The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

Klaus Podar; Kenneth C Anderson

doi:10.1182/blood-2004-07-2909

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

Klaus Podar, Kenneth C Anderson

Research output: Journal article (peer-reviewed) › Review article

316 Citations (Scopus)

Abstract

Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome.

Original language	English
Pages (from-to)	1383-1395
Number of pages	13
Journal	Blood
Volume	105
Issue number	4
DOIs	https://doi.org/10.1182/blood-2004-07-2909
Publication status	Published - 15 Feb 2005
Externally published	Yes

Keywords

Animals
Hematologic Neoplasms/blood
Humans
Neovascularization, Pathologic/blood
Vascular Endothelial Growth Factor A/biosynthesis

Access to Document

10.1182/blood-2004-07-2909

Cite this

@article{3ec09d1dbef74e12b629e5d18955e69e,

title = "The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications",

abstract = "Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome.",

keywords = "Animals, Hematologic Neoplasms/blood, Humans, Neovascularization, Pathologic/blood, Vascular Endothelial Growth Factor A/biosynthesis",

author = "Klaus Podar and Anderson, {Kenneth C}",

year = "2005",

month = feb,

day = "15",

doi = "10.1182/blood-2004-07-2909",

language = "English",

volume = "105",

pages = "1383--1395",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - The pathophysiologic role of VEGF in hematologic malignancies

T2 - therapeutic implications

AU - Podar, Klaus

AU - Anderson, Kenneth C

PY - 2005/2/15

Y1 - 2005/2/15

N2 - Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome.

AB - Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome.

KW - Animals

KW - Hematologic Neoplasms/blood

KW - Humans

KW - Neovascularization, Pathologic/blood

KW - Vascular Endothelial Growth Factor A/biosynthesis

UR - http://www.scopus.com/inward/record.url?scp=13544255403&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-07-2909

DO - 10.1182/blood-2004-07-2909

M3 - Review article

C2 - 15471951

SN - 0006-4971

VL - 105

SP - 1383

EP - 1395

JO - Blood

JF - Blood

IS - 4

ER -

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this